title: Successful desensitization of a patient with rituximab hypersensitivity.
abstract: Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.
authors: Department of Hematology, Ankara University, Cebeci, 06590 Ankara, Turkey.
authors: Pinar
authors: P
authors: Ataca
authors: Department of Hematology, Ankara University, Cebeci, 06590 Ankara, Turkey.
authors: Erden
authors: E
authors: Atilla
authors: Department of Pulmonary Medicine, Immunology and Allergy Clinic, Ankara University, Cebeci, 06590 Ankara, Turkey.
authors: Resat
authors: R
authors: Kendir
authors: Department of Pulmonary Medicine, Immunology and Allergy Clinic, Ankara University, Cebeci, 06590 Ankara, Turkey.
authors: Sevim
authors: S
authors: Bavbek
authors: Department of Hematology, Ankara University, Cebeci, 06590 Ankara, Turkey.
authors: Muhit
authors: M
authors: Ozcan